Skip to main content
  • English
  • Français
  • About Us
    • About Us
    • Our Purpose and Identity
    • Integrated Report 2021
    • Governance
      • Governance
      • Board of Directors
      • Executive Committee
    • Where we are
    • Through time
    • All Our Stories
      • All Our Stories
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
  • Your Health
    • Your Health
    • Health and Well-Being
    • Diabetes and Cardiovascular Diseases
    • Specialty Care
      • Specialty Care
      • Rare Diseases
      • Rare Blood Disorders
      • Neurology
      • Immunology
      • Oncology
        • Oncology
        • When Cancer Grows Old
          • When Cancer Grows Old
          • Contributions Initiative
          • Global collaboration
      • Patient Support
    • Vaccines
      • Vaccines
      • The Value of vaccines
      • How immunization works
      • Infectious Disease and Vaccines
        • Infectious Disease and Vaccines
        • COVID-19
        • Influenza
        • Meningococcal Meningitis
        • Pertussis
        • Poliomyelitis
        • Respiratory Syncytial Virus
        • Discover more
        • Research and Innovation
      • Vaccines Production
      • Vaccines Stories
    • Taking Medicines Safely
    • Patient Safety at Sanofi
  • Science & Innovation
    • Science & Innovation
    • Partnering
      • Partnering
      • Let's partner
      • Areas of Interest
        • Areas of Interest
        • China & Emerging Markets
        • Digital
        • General Medicines
        • Immunology
        • Neuroscience
        • Oncology
        • Out-Licensing
        • Rare Diseases
        • Technology Platforms
        • Vaccines
      • Meet the team
    • Research & Development
      • Research & Development
      • Sanofi Pipeline
      • Vaccines
      • Immunology and Inflammation
      • Neurology
      • Oncology
      • Pioneering Technology Platforms
        • Pioneering Technology Platforms
        • Genomic Medicine Technology Platform
        • mRNA Technology: Vaccines and Beyond
        • NANOBODY® Technology Platform
        • SYNTHORIN™ Technology Platform
      • Rare Blood Disorders R&D
      • Rare Diseases
      • Voices from the Lab
    • Clinical Trials & Results
      • Clinical Trials & Results
      • Phases
      • Our disclosure commitments
        • Our disclosure commitments
        • Sanofi Pharma
        • Sanofi Genzyme
        • Sanofi Pasteur
      • Our data sharing commitments
      • Managed Access Programs (MAPs)
      • Investigator Sponsored Studies and Externally Sponsored Collaboration
    • Collaboration & Awards
      • Collaboration & Awards
      • Europe
        • Europe
        • iAwards
        • iDEA-iTECH
      • North America
        • North America
        • iAwards
        • iDEA-iTECH
      • China
    • Science Stories
  • Our Responsibility
    • Our Responsibility
    • Access to Quality Healthcare – Sanofi Global Health
    • Environmental sustainability
    • Diversity, Equity and Inclusion
      • Diversity, Equity and Inclusion
      • Making an Impact
      • A Million Conversations
      • Global Poll
      • Board & Employee Groups
      • Gender Balance
        • Gender Balance
        • Women@Sanofi
      • Our Partners
      • Our LGBTQ+ Voice
      • Allyship
    • Healthcare for all
      • Healthcare for all
      • Humanitarian Aid Programs
      • Contributing to the eradication, elimination and control of some infectious diseases
      • Fighting Against Falsified Medicine
      • Serving the needs of patients with non-communicable diseases
    • Corporate Citizenship
    • Foundation S (Endowment Fund)
    • Ethics & Transparency
      • Ethics & Transparency
      • Patient Safety at Sanofi
      • Our Code of Conduct
    • Suppliers
    • Document center
      • Document center
      • All factsheets
      • Access to Healthcare and Pricing
      • Country reports and other documents
      • CSR Strategy and Value Creation
      • Duty of Vigilance incl. Supply Chain
      • Environment
      • Responsible Business
      • Governance, Controls and Procedures
      • Reporting Frameworks and Indicators
      • Social incl. Communities
  • |
  • Careers
    • Careers
    • Explore our career opportunities
    • A range of possibilities
      • A range of possibilities
      • Market access
      • Marketing
      • Medical
      • Production
      • Research & Development
      • Consumer Healthcare
      • Vaccines careers
      • Student / Graduate / Young Professionals
      • Discover more possibilities
    • Grow with us
      • Grow with us
      • Diversity & Inclusion
      • Development opportunity: how Sanofi empowers you
      • Benefits
  • Investors
    • Investors
    • Financial Calendar & Events
      • Financial Calendar & Events
      • Quarterly earnings at a glance
      • Investor presentations
      • Annual General Meetings
      • Broker conferences
    • Environmental, Social, Governance
      • Environmental, Social, Governance
      • Our Latest news
      • Our Double Materiality Assessment
      • ESG Newsletters
    • Corporate governance
      • Corporate governance
      • Governance
      • Board of Directors
      • Executive Committee
      • Specialist committee
      • Compensations
      • Standards & rules
      • Regulated agreements
      • Internal Control
    • Sanofi share and ADRs
      • Sanofi share and ADRs
      • Sanofi stock chart
      • Shareholding calculator
      • Dividends
      • ADRs
      • Shareholding structure
      • Vara consensus
      • Shares & voting rights
      • Share repurchases
    • Reports and publications
      • Reports and publications
      • Financial and CSR reports
      • Shareholder publications
    • Individual Shareholders
      • Individual Shareholders
      • Welcome to Sanofi
      • Being a shareholder
        • Being a shareholder
        • Five reasons to be a Sanofi shareholder
        • How to buy Sanofi shares
        • Registered shares
      • Shareholder events
        • Shareholder events
        • Financial Calendar
        • Annual General Meetings
        • Participate in General Meetings
      • Reports and publications
        • Reports and publications
        • Financial and CSR reports
        • Shareholder publications
      • Shareholders committee
    • Regulated information
    • Fixed Income
    • Contacts
  • Media
    • Media
    • Press releases
      • Press releases
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
    • Articles
      • Articles
      • 2019
    • Contacts
    • Media Alert
  • |
  • Paris 2024 Partnership
Worldwide
EN
  • EN
  • FR

MEDIA

Press Releases 2023

  • Home
  • Media
  • Press releases
  • 2023
March 21, 2023
Press releases
Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis 
March 18, 2023
Press releases
Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis
March 16, 2023
Press releases
Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance
March 13, 2023
Press releases
Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)
March 7, 2023
Press releases
Press Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review
March 2, 2023
Press releases
Press Release: Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIO™ to redefine expectations for treatment of children <12 years of age with hemophilia A
February 24, 2023
Press releases
ALTUVIIIO™ approved by the U.S. FDA: this positive event triggers impairment reversal, positively impacting 2022 IFRS net income; no change on business net income (non-IFRS)
February 24, 2023
Press releases
Press release: New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease
February 23, 2023
Press releases
Media Update: New data for tolebrutinib, Sanofi’s investigational brain-penetrant BTK inhibitor, showed significant effect on CNS immune mediators that drive MS disease progression 
February 23, 2023
Press releases
Press Release: FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection
February 21, 2023
Press releases
Media Update: Pediatric research at ReSViNET 2023 underscores Beyfortus’ potential to prevent RSV disease in infants
February 13, 2023
Press releases
Press Release: Sanofi announces change in R&D leadership
February 3, 2023
Press releases
Press Release : Strong sales performance and double digit EPS growth marking the achievement of the 2022 profitability milestone
January 30, 2023
Press releases
Press Release:  Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis
January 27, 2023
Press releases
Press Release: Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis
January 25, 2023
Press releases
Press Release: NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia A
January 11, 2023
Press releases
Press Release: Sanofi Ventures announces multi-year capital commitment from Sanofi, increasing evergreen fund to $750M
January 5, 2023
Press releases
Press Release: FDA accepts nirsevimab application as first protective option against RSV disease for all infants
January 4, 2023
Press releases
Press Release: Availability of the Q4 2022 Memorandum for modelling purposes
Sanofi

    Follow us

  • Contact
  • Legal notice
  • Privacy & Data Protection
  • Cookies policy
  • Corporate code of ethics
  • Our publications
  • Sitemap
  • Our websites
  • Accessibility: partial compliance

© Sanofi 2004-2022 - All rights reserved

You are about to leave sanofi.com

If you wish to continue to this external website, click Proceed.

It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.

PROCEED